Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. is a U.S.-based clinical-stage biotherapeutics company developing oral delivery technology for biologics and other drugs. Its core platform, the RaniPill capsule, is designed to deliver drug substances such as antibodies, proteins, peptides, and oligonucleotides through the gastrointestinal tract, with development activities centered in the United States and intended for global use.

−2 290,9 %

−1 817,1 %

+58,9 %

4.21

4.21

— Rani Therapeutics Holdings, Inc.
%
RaniPill GO20% Microtablet-based oral capsule designed to deliver small biologic doses with high bioavailability.
RaniPill HC20% High-capacity capsule under development for liquid payload delivery of larger biologics.
Partnered development and evaluation services60% Technology evaluation, transfer, and collaboration work performed for third-party biopharma partners.

Rani’s customers are primarily biopharmaceutical companies that want to convert injectable biologics into oral...

  • Biopharmaceutical collaboration partnersprimary

    Companies that license or co-develop the RaniPill platform for specific biologic or drug programs.

  • Technology evaluation customerssecondary

    Partners that pay for evaluation services to assess whether their compounds can be delivered orally.

  • Future commercial pharma customersemerging

    Drug developers that may adopt the platform for approved products if clinical and regulatory milestones are met.

Rani is headquartered in the United States and conducts its development, engineering, and manufacturing activities...

  • •Headquartered and primarily operated in the United States
  • •Development and manufacturing capabilities are built in-house in the U.S.
  • •Future commercialization is planned for the U.S., Europe, and Asia
  • •Partner-led expansion could broaden market reach without a large sales force
  • •Regulatory approvals will determine which countries can use the platform

Rani’s strategy is to advance the RaniPill platform through clinical development while partnering with biopharma...

01
Advance clinical validation of the RaniPill platformshort-term

Human data is needed to prove oral delivery performance and support regulatory progress.

02
Secure and expand biopharma collaborationsshort-term

Partner programs can create non-dilutive funding and validate the platform with named drug developers.

03
Scale manufacturing and device productionmedium-term

Commercial adoption will require reliable capsule manufacturing and supply chain control.

Rani faces the typical risks of a clinical-stage biotechnology company: uncertain clinical outcomes, regulatory...

critical

Clinical and regulatory failure

The RaniPill platform must prove safety, bioavailability, and efficacy across programs.

Scope
RaniPill GO and RaniPill HC
Materiality
high
high

Lack of commercial product revenue

The company is still in development, so revenue depends on future approvals and partner execution.

Scope
Platform-wide
Materiality
high
high

Partner concentration and collaboration dependence

A major portion of future economics may depend on one or a few collaboration agreements.

Scope
Chugai collaboration
Materiality
high
high

Financing and dilution risk

Development and manufacturing require capital before product sales are available.

Scope
Corporate funding
Materiality
high
medium

Supply chain and manufacturing execution

The platform relies on third-party APIs/components and complex device manufacturing.

Scope
Single-source suppliers, automated lines
Materiality
medium
medium

Nasdaq listing compliance

Failure to maintain listing standards could reduce liquidity and investor access.

Scope
Public equity market access
Materiality
medium
Contract revenue recognition
Small but important for collaboration economics
R&D expense classification
Primary driver of period expenses
Capitalization of manufacturing assets
Affects balance sheet size and near-term earnings
Non-controlling interest accounting
Impacts earnings attribution

Rein Therapeutics, Inc.

RNTX · Pharmaceutical Preparations

Tvardi Therapeutics, Inc.

TVRD · Pharmaceutical Preparations

DarioHealth Corp.

DRIO · Surgical & Medical Instruments & Apparatus

PALISADE BIO, INC.

PALI · Biological Products, (No Diagnostic Substances)

Savara Inc

SVRA · Pharmaceutical Preparations

ANI PHARMACEUTICALS INC

ANIP · Pharmaceutical Preparations

: 29.4.2026